| 摘要 |
PURPOSE:The titled prescription medicine useful for treating recurrent, progressive and terminal cancerous patients, promoting intrinsic carcinostatic action, consisting of BCG or Corynebacterium parvum, OK-432 and IFN. CONSTITUTION:An intradermic injection prescription medicine consisting of 0.005-5mg BCG or Corynebacterium parvum acting as a priming agent, 1-4 KE of OK-432 and 200,000-1,000,000 unit IFN. Intradermal prescription, for example, is carried out by intradermic injection of BCG or Corynebacterium parvum on first day, OK-432 after 7-10 days and OK-432 and IFN after 12-16 days. |
